Low incidence of gastrointestinal adverse events over time with a fixed‐ratio combination of insulin glargine and lixisenatide versus lixisenatide alone

This post hoc analysis of gastrointestinal (GI) adverse events (AEs) from the phase 3 LixiLan‐L (NCT02058160) and LixiLan‐O (NCT02058147) trials aimed to determine the frequency and timing of nausea, vomiting, and diarrhoea for iGlarLixi, a titratable, fixed‐ratio combination of insulin glargine 100...

Descripción completa

Detalles Bibliográficos
Autores principales: Trujillo, Jennifer M., Roberts, Michelle, Dex, Terry, Chao, Jason, White, John, LaSalle, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221077/
https://www.ncbi.nlm.nih.gov/pubmed/29923298
http://dx.doi.org/10.1111/dom.13444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221077/
https://www.ncbi.nlm.nih.gov/pubmed/29923298
http://dx.doi.org/10.1111/dom.13444

Ejemplares similares